

Introduction to the NCI's Division of Cancer Biology

Dave Miller, Ph.D. and Christine Nadeau, Ph.D.

Program Directors
NCI/NIH

Organization of the National Cancer Institute

Extramural Programs (~75% budget, ~7000 grants)

- Division of Cancer Biology (DCB)
 - DCB (~2000 grants)
- Division of Cancer Treatment and Diagnosis (DCTD)
- Division of Cancer Prevention (DCP)
- Division of Cancer Control and Population Sciences (DCCPS)
- Division of Extramural Activities (DEA)

The [NCI Extramural Program](#) consists of five divisions. Four of these divisions coordinate grant activities in [cancer biology](#), [cancer control and population sciences](#), [cancer prevention](#), and [cancer treatment and diagnosis](#).

The [DEA](#) manages the peer review process and provides support for funding opportunity development and portfolio analysis.

The Division of Cancer Biology (DCB)

Office of the Director

Director: Daniel Gallahan, Ph.D.

Deputy Director: Shannon Hughes, Ph.D.

Branches

DNA and Chromosome Aberrations

Chief: Ian Fingerman, Ph.D.

Cancer Cell Biology

Chief: Rihab Yassin, Ph.D.

Cancer Immunology, Hematology and Etiology

Chief: Kevin Howcroft, Ph.D.

Biophysics, Bioengineering, and Computational Sciences

Chief: Jennifer Couch, Ph.D.

Tumor Biology and Microenvironment

Chief: Jeffrey Hildesheim, Ph.D.

Tumor Metastasis

Chief: Joanna Watson, Ph.D.



- DCB**
- Research Portfolio >
- Research Programs >
- Funding >
- Researcher Resources
- News & Events >
- About DCB >




Division of Cancer Biology

The Division of Cancer Biology (DCB) supports basic research in all areas of cancer biology at academic institutions and research foundations across the United States. As part of the National Cancer Institute, DCB provides funding for research that investigates the basic biology behind cancer.

Research in the field of basic cancer biology focuses on

Connect with DCB

- [Twitter: @NCICancerBio](#)
- [LinkedIn: NCI Division of Cancer Biology](#)
- [Subscribe to News from DCB](#)



DCB

[Research Portfolio](#) >

[Research Programs](#) >

[Funding](#) >

[Researcher Resources](#)

[News & Events](#) >

About DCB

[Contact & Staff](#)

[Progress](#) >

Contact the Division of Cancer Biology

Division of Cancer Biology
9609 Medical Center Drive MSC 9747/9748
Bethesda, MD 20892

[Follow DCB on Twitter](#) 

ON THIS PAGE

- [Office of the Director](#)
- [Cancer Cell Biology Branch](#)
- [Cancer Immunology, Hematology, and Etiology Branch](#)
- [DNA and Chromosome Aberrations Branch](#)
- [Biophysics, Bioengineering, and Computational Sciences Branch](#)
- [Tumor Biology and Microenvironment Branch](#)
- [Tumor Metastasis Branch](#)
- [Administrative Resource Center](#)



Tumor Metastasis Branch

The Tumor Metastasis Branch plans, develops and directs the Division's research program in tumor metastasis, focusing on mechanisms of metastasis and metastatic niches, circulating tumor cells, dormancy, and angiogenesis and vasculogenesis.

More information on research supported by this branch is available in the [Research section](#).








Phone: (240) 276-6220

Fax: (240) 276-7866

| Name & Position | Email | Areas of Expertise |
|---|--|---|
| Joanna Watson, Ph.D. <i>Chief</i> | watsonjo@mail.nih.gov | Circadian rhythms, cancer cachexia, circulating tumor cell biology, and mechanisms of metastasis |
| Grace Ault, Ph.D. <i>Program Director</i> | aultg@mail.nih.gov | Cell invasion and migration, epithelial-mesenchymal transition, metabolic adaptation to the microenvironment, and growth factor signaling |
| Justin Benavidez, Ph.D. <i>Program Director</i> | justin.benavidez@nih.gov | Biological sciences, developmental biology, and cancer metastasis |
| Brunilde Gril, Ph.D. <i>Program Director</i> | grilbrun@mail.nih.gov | Brain metastases, blood-brain/tumor barrier, experimental therapies for metastasis, and receptor tyrosine kinase signaling |
| Christine Nadeau, Ph.D. <i>Program Director</i> | christine.nadeau@nih.gov | Mammalian models of cancer, Notch signaling, breast cancer, and systemic immunity |



DCB-Supported Research Programs



DCB

[Research Portfolio](#) >

[Research Programs](#) >

Funding

Funding Opportunities

[Funding Resources](#)
[Researcher Resources](#)
[News & Events](#) >

[About DCB](#) >

[Progress](#) >

DCB Funding Opportunities

Notices of Funding Opportunities (NOFOs)

| Title | Announcement Number | Opening Date | Expiration Date | Activity Code |
|--|-------------------------------|--------------|-----------------|---------------|
| Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | NOT-CA-24-016 | 12/05/2023 | 11/17/2026 | R21 |
| Notice of Request for Information (RFI) to Facilitate Cancer Systems immunology Research | NOT-CA-24-003 | 11/06/2023 | 02/29/2024 | N/A |
| Notice of Special Interest (NOSI): Research Projects to Develop Oncoaging Models for Cancer Research | NOT-CA-23-092 | 10/16/2023 | 07/31/2027 | N/A |
| Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk | NOT-CA-23-089 | 08/31/2023 | 09/08/2024 | N/A |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | PAR-23-281 | 09/05/2023 | 09/08/2026 | R01 |



DCB Supported Resources

- Additional research resources:
 - [The NCI Mouse Repository](#)
 - [GM/CA X-ray Beamline](#)
 - [Chernobyl Tissue Bank \(CTB\)](#)
 - [The International Registry of Werner Syndrome](#)
 - [NIH MHC Tetramer Program](#)
 - [Reagents Available to NCI-funded Researchers](#)
 - [Cancer Complexity Knowledge Portal](#)
- Various webinar series, workshops, and opportunities such as the [DCB Summer Undergraduate Research Program](#)

The most important advice... ...talk to your program director!


David Miller, PhD
Program Director
Biophysics, Bioengineering, and
Computational Sciences Branch

david.miller3@nih.gov

Christine Nadeau, PhD
Program Director
Tumor Metastasis Branch

240-276-7491

christine.nadeau@nih.gov



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol

Division of Cancer Control & Population Sciences: Overview and Priority Highlights

*Paige Green, Ph.D., M.P.H.
Chief, Basic Biobehavioral and Psychological Sciences Branch
Behavioral Research Program*



DIVISION OF CANCER CONTROL & POPULATION SCIENCES

FROM
INQUIRY
TO IMPACT

Working Together to
Advance Cancer
Research



A WORLD WITHOUT THE BURDEN OF CANCER



OUR MISSION

Advance research in cancer control and population sciences to eliminate cancer and its consequences for all

“Cancer control science is the conduct of basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that, independently or in combination with biomedical approaches, reduce cancer risk, incidence, morbidity and mortality, and improve quality of life.” Cancer Control Program Review Group, 1998—modified



OUR CORE VALUES

01.

Serving the public good

02.

Inclusion and belonging

03.

Foresight and innovation



04.

Collaboration and partnership


05.

Integrity

06.

Excellence and rigor

ORGANIZATIONAL LANDSCAPE



IMPLEMENTATION SCIENCE RESEARCH

Improving the impact of cancer control and population science on the health and health care of the population, and fostering the rapid integration of research, practice, and policy.

FEATURED INITIATIVES



The initial Consortium for Cancer Implementation Science (CCIS) meeting, held July 2019, delved into three main categories of focus: building capacity, increasing collaboration, and supporting implementation science activities in cancer. CCIS seeks to develop a new approach for the field to work together to address key challenges and identify and develop new areas of investigation towards advancing the implementation science agenda in cancer control.

[Learn More About CCIS](#)



These collaborative research centers, supported through the Cancer MoonshotSM, are designed to improve cancer control through creation of "laboratories" that study implementation efforts in clinical and community settings, develop novel IS methods and measures, execute innovative pilot projects, enhance data resources, and disseminate results among the cancer research community. The goal of the network is to reduce the burden of cancer by enhancing the design and delivery of implementation strategies for evidence-based cancer control.

[Learn More About ISC3](#)

HEALTH DISPARITIES & HEALTH EQUITY RESEARCH

DCCPS seeks to eliminate cancer-related disparities by promoting and conducting health equity research that identifies and addresses the mechanisms contributing to disparities across the cancer control continuum and throughout the human lifespan.

Learn more about the background and mission of Health Disparities and Health Equity.

Spotlight



WEBINAR SERIES

[Context of Poverty Webinar Series](#)

This new webinar series delves into the context of poverty, where esteemed researchers will present their work focusing on different aspects of poverty.



WEBINAR

[Informational Webinar: What's New with the Intervention Research to Improve Native American Health \(IRINAH\) NOFOs?](#)

Webinar being held on Thursday, January 25, 2024 will explain the goals and highlight what is new with the IRINAH NOFOs. Details and registration information provided.



FEATURE

[Biden-Harris Administration Launches Initiative to Improve Cancer Outcomes in Low-Income Areas](#)

Today, the Biden-Harris Administration awarded \$50 million to launch the Persistent Poverty Initiative, an initiative to alleviate the cumulative effects of persistent poverty on cancer outcomes by building research capacity, fostering cancer prevention research, and promoting the implementation of community-based programs.



Funding Opportunities

[Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities](#)

EXPIRATION DATE: January 08, 2026

[Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs](#)

EXPIRATION DATE: May 08, 2024

[Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities](#)

EXPIRATION DATE: January 08, 2025

[View More Funding Opportunities](#)

HEALTH DISPARITIES & HEALTH EQUITY RESEARCH

FEATURED INITIATIVES

Rural Cancer Control



Rural communities face disadvantages, which contribute to higher incidence and mortality rates for many cancers, and higher average mortality rates for all cancer sites combined.

Geographically Underserved Areas



Communities experiencing high or persistent poverty are at an increased risk of cancer caused by environmental, occupational, and recreational exposures, and lifestyle factors.

Native American Health




Native American populations are disproportionately affected by many cancers, with detection and diagnoses often occurring at later stages.

Poverty





Poverty and accompanying factors such as education, housing, and employment have tremendous effects on the health of communities and their populations.

CANCER SURVIVORSHIP



CANCER SURVIVORSHIP RESEARCH & PHASES OF SURVIVORSHIP



BEHAVIORAL RESEARCH PROGRAM

The Behavioral Research Program initiates, supports, and evaluates a comprehensive program of research to increase the breadth, depth, and quality of behavioral research in cancer prevention and control.

PROGRAM BRANCHES

Basic Biobehavioral and Psychological Sciences Branch (BBPSB)

BBPSB advances research in biobehavioral mechanisms and psychological processes to reduce cancer risk and improve outcomes.

Health Behaviors Research Branch (HBRB)


HBRB supports and catalyzes research to promote healthy lifestyle behaviors for cancer prevention and control.

Health Communication and Informatics Research Branch (HCIRB)

HCIRB advances research on the processes and effects of communication and informatics across the cancer control continuum.


Tobacco Control Research Branch (TCRB)

TCRB leads and collaborates on research and disseminates evidence-based findings to prevent, treat, and control tobacco use.




EPIDEMIOLOGY & GENETICS RESEARCH PROGRAM

Supporting research in human populations to understand determinants of cancer occurrence and outcomes and translating findings to clinical and public health interventions.



HEALTHCARE DELIVERY RESEARCH PROGRAM

The mission of the Healthcare Delivery Research Program (HDRP) is to advance innovative research to improve the delivery of cancer-related care, thereby improving health for individuals and populations.



SURVEILLANCE RESEARCH PROGRAM

Cancer surveillance provides a quantitative portrait of cancer and its determinants in a defined population. The core functions of cancer surveillance are the measurement of cancer incidence, morbidity, survival, and mortality for persons with cancer.

<https://surveillance.cancer.gov/>

SPOTLIGHT ON...

Surveillance, Epidemiology, and End Results (SEER) Program

SEER is an authoritative source for cancer statistics in the United States.

It provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).

[Visit SEER](#)

WHAT'S NEW

- SEER 1975-2020 Cancer Data Available**
Includes the release of new statistics and updated software.
Updated: April 19, 2023
- Impact of COVID on 2020 SEER Cancer Incidence Data**
Updated: April 19, 2023
- National Childhood Cancer Registry Explorer (NCCR*Explorer)**
Released: November 8, 2021

<https://seer.cancer.gov/>

FROM INQUIRY TO IMPACT

Working Together to
Advance Cancer
Research



2023 OVERVIEW AND HIGHLIGHTS

 NATIONAL CANCER INSTITUTE
Division of Cancer Control & Population Sciences



HEALTH EQUITY

"Data are critical in understanding place-based poverty and the resultant disparities among cancer survivors."

- New data & cancer epidemiology cohorts
- Persistent Poverty initiative
- Advancing Cancer Control Equity Research through Transformative Solutions initiative
- Improve Care & Outcomes for Cancer Survivors from Sexual & Gender Minority Populations initiative





DATA STRATEGIES

- SEER linkages with external data sources
- FAIR population science data infrastructure
- Secondary use of data and methods resources

“Leveraging partnerships will be critical for moving DCCPS's data strategies forward, particularly for addressing gaps in infrastructure.”



EVIDENCE-BASED CANCER CONTROL POLICY RESEARCH

“We will focus on evaluating existing policies and studying new policy approaches to improve cancer outcomes and health equity.”

- Tobacco control strategies
- HPV Cancer Center Consortium
- Consortium for Cancer Implementation Science
- Administrative Supplement to Support Health Policy Research in Cancer Prevention and Control initiative



DIGITAL HEALTH



- Cancer Telehealth Research Centers of Excellence
- Administrative Supplement Digital Health as a Solution for Patient-Provider Communication initiative
- National Institutes of Health-National Science Foundation Smart Health initiative



MODIFIABLE RISK FACTORS

- Population approaches to reducing alcohol-related cancer risk
- Methods for integrating analysis of 24-hour behavioral patterns
- Food is Medicine research opportunities
- Systems epidemiology to address modifiable cancer risk factors
- Community-engaged initiatives for obesity policy





CLIMATE CHANGE

- Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) ([PA-20-172](#))
- Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional) ([PAR-23-153](#))
- Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 – Clinical Trial Not Allowed) ([RFA-ES-22-003](#))
- Notice of Special Interest (NOSI): Climate Change and Health ([NOT-ES-22-006](#))
- Notice of Special Interest (NOSI): Climate Change and Health Administrative Supplements ([NOT-HD-23-006](#))
- Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional) ([RFA-ES-23-007](#))

- Identify and address cumulative exposures and disruptions
- Link environmental data to cancer control and population science data



OPPORTUNITIES FOR RESEARCHERS

- Exploratory Grants in Cancer Control ([PAR-21-341](#))
- Modular R01s in Cancer Control and Population Sciences ([PAR-21-190](#))
- Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts ([PAR-22-161](#))
- Research Opportunities in Established Cancer Epidemiology Cohort Studies ([PAR-22-162](#))
- Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional) ([PAR-23-152](#), [PAR-23-153](#))
- Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) ([PAR-23-273](#))


- Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) ([PAR-23-244](#))
- Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) ([PAR-23-292](#))
- Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors ([NOT-CA-22-029](#))
- Addressing Cancer-related Financial Hardship to Improve Patient Outcomes ([NOT-CA-22-045](#))
- Pragmatic Trials Across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) ([PAR-22-256](#))
- Dissemination and Implementation Research in Health (Domestic and International Funding Opportunity) ([PAR-22-105](#), [PAR-22-106](#), [PAR-22-109](#))

FOR ADDITIONAL INFORMATION

STAY CURRENT WITH DCCPS



Visit: <https://cancercontrol.cancer.gov/about-dccps/connect-with-dccps>
<https://cancercontrol.cancer.gov/overview-highlights/2023/>



FOR ADDITIONAL INFORMATION



paige.green@nih.gov



240.276.6899





**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol



DCP, NCI Research Resources for Investigators

Asad Umar, DVM, PhD

Senior Advisor to Director

Chief of Gastrointestinal & Other Cancers Research Group, DCP



DISCLAIMER

- *The opinions expressed are my own and this material should not be interpreted as representing the official viewpoint of the U.S. Department of Health and Human Services, the National Institutes of Health or the National Cancer Institute*
- *These are personal observations made while working at the NIH and nothing contained within should be viewed as prescriptive of or an endorsement by the NIH or NIH staff. These suggestions have pluses, minuses, and caveats. Seek out multiple sources of advice and weigh the potential pros and cons. This is not a comprehensive list. This is a compilation of common resources for new and early-stage investigators seeking NIH funding*


The Mission of the Division of Cancer Prevention (DCP)

“The NCI Division of Cancer Prevention leads, supports, and promotes rigorous, innovative research and training to reduce risks, burdens, and consequences of cancer to improve the health of all people.”

Estimated Timeline of Progression of Selected Cancers and Pre-malignant Stages at Which Specific Genes Contribute to Carcinogenesis



Impact of Effective Interventions on Carcinogenesis



Translational Research at DCP



CRP

CAP-IT
NP
CIP-
Net

PREVENT

CP-CTNet

NCORP

Cancer Preventive Agent Pipeline

EDRN
PCA
PCDC

CSRN
NCORP

Cancer Biomarkers for Screening and Early Detection Pipeline

TBD

NCORP

Cancer Symptom Management and Care Pipeline

Preclinical & Clinical Cancer Preventive Interventions

The PREVENTative Development Program for Cancer Prevention & DCP Phase 2 Consortia

Cancer Preventive Agent Discovery Programs

- Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
- Cancer Immunoprevention Network (CIP-Net)
- Discovery and Development of Natural Products for Cancer Interception and Prevention (DDNP-CIP)

Preclinical Development
Preliminary Efficacy & Safety

PREVENT Cancer Program

Cancer Preventive Efficacy Evaluation:

Efficacy:

- Tumor Incidence/Multiplicity
- Genomic, Proteomic, & Metabomic Profiles
- Safety & Toxicity (PK/PD studies)


DCP Phase I/II
Clinical Trials Consortia

- Biomarker validation
- Efficacy
- Safety

DCP Phase III
Clinical Trials
- NCORP & MB-CCOPs

What Applicants Need to Know About Program Directors at DCP?

- **General Resources and Tips for Researchers**
- **Grantsmanship Tools**
- **Specific Funding Opportunities at DCP**



NIH Matchmaker Tool


Enter abstracts or other scientific text to find potential Program Officials, ICs, and review panels for your research. ?

Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity and age. With the increasing prevalence of obesity and conflicting data regarding the effect of aspirin in older adults, understanding the potential association of aspirin use with cancer mortality according to body mass index (BMI) and age is imperative.; ; Objectives: To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform an exploratory analysis of the association of aspirin use with mortality stratified by BMI; Design, setting, participants: This cohort study

12,207 characters left

<https://reporter.nih.gov/matchmaker>

- Similar Projects
- Similar Program Officials



Reset

Search

Matchmaker Results

150 POs

Importance: Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity and age. With the



Search

Projects Program Officials


<https://reporter.nih.gov/matchmaker>

Filters

- Active Projects
- > Fiscal Years
- > Agencies
- > Activity Codes
- > Program Officials
- > Study Sections



| Program Official | IC | Contact Information | Projects |
|---|-------|--|--------------------|
| KUCZMARSKI, ROBERT J | NIDDK | View Email Contact info is hidden by default for privacy | 23 |
| KARRAKER, AMELIA WILKES | NIA | | 17 |
| LAI, GABRIEL Y | NCI | | 10 |
| OSGANIAN, VOULA | NIDDK | | 8 |
| BRESLAU, ERICA S | NCI | | 7 |
| ELENA, JOANNE W | NCI | | 6 |
| SALIVE, MARCEL | NIA | | 6 |
| LAM, TRAM K | NCI | | 6 |
| TILAHUN, MULUALEM ENYEW | NCI | | 6 |
| UMAR, ASAD | NCI | | 6 |



What Might be a Suitable Study Section for Your Grant



The screenshot shows the NIH Assisted Referral Tool (ART) interface. At the top, there is a navigation bar with the NIH logo, 'Center for Scientific Review', and the title 'Assisted Referral Tool (ART)'. Below this is a search bar containing 'SRG' and a 'Submit' button. To the right of the search bar is a link for 'Animal Usage?'. Below the search bar is a text area with the instruction: 'Enter application text and hit the Submit button to get a list of relevant study sections in two groups, "Strong" and "Possible". Within a group, study sections are listed alphabetically by the SRG acronym.' Below this is a 'Title' field with a dropdown menu and a 'Sample Clear' button. At the bottom of the page, there are logos for the NIH, National Institutes of Health, USA.gov, and HHS Vulnerability Disclosure.

Find a Relevant Study Section for Your Grant



Assisted Referral Tool (ART)

[Help](#) | [Disclaimer](#) | [User Guide](#)

[ART Home](#) >> SRG

Animal Usage?

Enter application text and hit the Submit button to get a list of relevant study sections in two groups, "Strong" and "Possible". Within a group, study sections are listed alphabetically by the SRG acronym

Title

Optional but strongly recommended, as title concepts receive full weight in the models

Sample

Clear

Enter your application text here. Entering both Abstract and Specific Aims is recommended. Section subheaders and delimiters (e.g. 'Abstract') will be ignored. At least 10 scientific concepts from the RCDL Thesaurus must be detected for ART to submit your job.

Terms will be weighted by frequency of appearance in the text above. The process is automated and confidential. ART does not track or store submitted text. For more information consult the [User Guide](#).

Submit

Find a Relevant Study Section for Your Grant



Assisted Referral Tool (ART)

[Help](#) | [Disclaimer](#) | [User Guide](#)

[ART Home](#) >> [SRG](#) >> Report

Animal Usage?

Enter application text and hit the Submit button to get a list of relevant study sections in two groups, "Strong" and "Possible". Within a group, study sections are listed alphabetically by the SRG acronym

Title

Aspirin use has been associated with reduced risk of cancer incidence and mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity, age and immunologic age. With the increasing prevalence of obesity and conflicting data regarding the effect of aspirin in older adults, understanding the potential association of aspirin use with cancer mortality according to body mass index (BMI) and age is imperative. Objectives: To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) incidence and mortality among older adults and to perform an exploratory analysis of the association of aspirin use with cancer incidence and mortality we analyzed retrospective data from Prostate, Lung, Colorectal and Ovary Screening trial of NCI DCP.

Terms will be weighted by frequency of appearance in the text above. The process is automated and confidential. ART does not track or store submitted text. Characters left: 19115

| Relevance | SRG | RB | Membership | Name |
|-----------|------|------|------------|---|
| Strong | CHD | EPH | Roster | Cancer and Hematologic Disorders |
| Strong | CPSS | CDPT | Roster | Cancer Prevention Study Section |
| Strong | CRD | EPH | Roster | Cardiovascular and Respiratory Diseases |

Find Research Career Development Awards



Find Research Career Development Awards

About DBRW

Career Path

Programs

Institute/Program Matrix

Resources

Training

Fellowships

Career Development

Other Training-Related

Research Career Development Awards

RTCD Home > Programs

To provide individual and institutional research training opportunities (including international) to trainees at the undergraduate, graduate, and postdoctoral levels.

1. Select Role



Awardee



Appointee

2. Select Career Level

Select

APPLY FILTER

RESET FILTER

FAQs

- When submitting a K99/R00 application which involves human subjects, do I need a study record for each phase?
- Who do I contact for questions about my specific application?
- If there are problems with eRA Commons registration or with the grants.gov submission process, where can one get help?
- Who do I contact for questions about my specific institutional training application or grant?

**If You Need it on the Go,
There is an App for That™.**

Grants.gov

There is an App for Grants

The screenshot shows the Google Play Store interface for the Grants.gov app. The top navigation bar includes 'Categories', 'Home', 'Top charts', and 'New releases'. A left sidebar menu lists 'My apps', 'Shop', 'Games', 'Kids', 'Editors' Choice', 'Account', 'Payment methods', 'Play Points', 'My subscriptions', 'Redeem', 'Buy gift card', 'My wishlist', 'My Play activity', and 'Parent Guide'. The main content area features the Grants.gov app listing, which includes a large 'G' logo, the title 'Grants.gov', the subtitle 'Official Grants.gov App Education', a rating of 4.5 stars from 1,570 reviews, and an 'Install' button. Below the app listing is a large banner image of the 'G' logo and a filter overlay titled 'Find & filter opportunity most relevant to you'. The filter overlay shows options for 'Opportunity Status (2)', 'Funding Instrument Type', and 'Eligibility', with 'All Eligibilities' selected. To the right of the main listing, a 'Similar' section shows two other apps: 'GoFundMe - Online' and 'Child Support, Expense SupportPay', each with a 'See more' button.

Apps

Categories ▾ | Home | Top charts | New releases

My apps
Shop
Games
Kids
Editors' Choice

Account
Payment methods
Play Points **New**
My subscriptions
Redeem
Buy gift card
My wishlist
My Play activity
Parent Guide

Grants.gov
Official Grants.gov App Education
★★★★☆ 1,570
Everyone
You don't have any devices
You can share this with your family. [Learn more about Family Library](#)
Add to Wishlist

Install

Find & filter opportunity most relevant to you

Filter

Opportunity Status (2)

Funding Instrument Type

Eligibility

- All Eligibilities
- City or township government
- County governments (526)
- For profit organizations other businesses (302)
- Independent school districts
- Individuals (196)
- Native American tribal govern (Federally recognized) (394)

Similar **See more**

GoFundMe - Online
GoFundMe Inc
★★★★☆

Child Support, Expense SupportPay
★★★★☆



Attend Regional Seminar on Funding & Grant Administration



[Home](#) » [News & Events](#) » [Connect in Person](#) » [NIH Regional Seminars on Program Funding and Grants Administration](#)

NEWS & EVENTS

Latest News

Subscribe and Follow

Virtual Learning

Connect In Person

NIH Regional Seminars on Program Funding & Grants Administration

SBIR-STTR Engage & Connect

Loan Repayment Program (LRP) Contact & Engage

Office of Laboratory Animal Welfare (OLAW) Workshops

NIH Regional Seminars on Program Funding and Grants Administration

On This Page:

- [Upcoming Seminars](#)
- [Recent Seminars](#)
- [Subscribe for Email Updates](#)
- [OER Presenter and Grant Seminar Requests](#)



Each year, the Office of Extramural Research (OER) sponsors the NIH Regional Seminars on Program Funding and Grants Administration. These seminars are intended to help demystify the application and review process, clarify Federal regulations and policies, and highlight current areas of special interest or concern. The seminars serve the NIH mission of providing education and training for the next generation of biomedical and behavioral scientist. NIH policy, grants management, review and program staff provide a broad array of expertise and encourage personal interaction between themselves and seminar participants. The seminars are appropriate for grants administrators, researchers new to NIH, and graduate students.

Upcoming Events:

| DATES | LOCATION | AMBASSADORS | PROGRAM INFO |
|--|----------------|-------------|---|
| <p>New this year! 2022-2023 NIH Grants Conference & PreCon Events</p> | <p>Virtual</p> | <p>N/A</p> | <p>NEW NAME...NEW APPROACH...TIME TO PLAN YOUR JOURNEY! One Registration...One All-Access Conference Pass!</p> <p>August 2022 - January 2023: NIH PreCon Events These monthly events are focused on more in-depth views of NIH topics. Examples include Research Misconduct, Human Subjects, and International Collaborations.</p> <p>February 1-2, 2023: NIH Grants Conference: Funding, Policies, & Processes Make plans to take part in this 2-day conference, providing attendees with 25 different session options, over 30 on-demand videos, 1:1 Meet the Expert appointments, 45 NIH booths (many staffed), and so much more! Agenda: https://grants.nih.gov/learning-center/conference/2-day/agenda-at-a-glance</p> <p>Looking for presentation materials from the 2021 Fall NIH Virtual Seminar? Find them at https://grants.nih.gov/virtual-seminar-2021/presentations.html</p> <p>Questions? Email us: NIHGrantsEvents@nih.gov.</p> |

NIH regional seminar on program funding & grants administration

- Provides education and training for the next generation of biomedical and behavioral scientists
- Demystifies the application and review process
- Clarifies Federal regulations and policies
- Highlights current areas of special interest or concern
- Last virtual seminar on November 1-4, 2021
- Access last year's recorded presentations: <https://grants.nih.gov/virtual-seminar-2020/presentations.html>



<https://grants.nih.gov/grants/oer.htm>



Gain Review Experience Through the NIH Early Career Review (ECR) Program



COVID-19 Get the latest public health information from CDC: <https://www.cdc.gov/coronavirus>
Get the latest research information from NIH | [Español](#)


Coronavirus Guidance for NIH Applicants and Grantees:
https://grants.nih.gov/grants/natural_disasters/corona-virus.htm

Home > For Reviewers

Reviewer Recruitment

- [Reviewer Benefits](#)
- [Early Career Reviewer \(ECR\) Program](#)
- [How Regular Members of a Study Section Are Selected](#)

<https://public.csr.nih.gov/ForReviewers/BecomeAReviewer>



New and Early-Stage Investigators



New Investigator (NI):

In general, a Principal Investigator (PI) is considered a New Investigator if s/he has not previously competed successfully as PI for a substantial* NIH independent research award

[*Not including, R00,R03,R13,R15,R21,R25,R90,RL9,RL5,R34,R36,R41,R43,R55,R56,SC2,SC3,Fs,Ks,Ts,Ls,Gs,Ss]

Early Stage Investigator (ESI): A PI is considered an **Early Stage Investigator (ESI)** if s/he is **within 10 years** of completing his/her **terminal research degree** or is within 10 years of completing **medical residency** (or the equivalent) **[FY23 ESI Interim Payline=15%]**

MERIT AWARD (R37): ESI R01 applications that receive a score within the NCI payline for experienced and new investigators **[FY23 Established Investigator (EI) Interim Payline=10%]**

Multi-PI Grant: All MPIs must meet ESI or NI requirement

Extension of Early-Stage Investigator Status

NIH will consider requests to extend the ESI status period for reasons that can include the following, as determined on a case-by-case basis at the sole discretion of NIH

- Medical concerns
- Disability or illness
- Family care responsibilities
- Childbirth
- Clinical Loan Repayment Requirements
- Natural or other disasters
- Active duty military service
- Research impacted by COVID-19 during your ESI period

Early Stage Investigator Policies: Requesting an Extension of the ESI Period [NOT-OD-09-034]

https://era.nih.gov/erahelp/ESIE_ext/Default.htm#cshid=4

Additional Tips:

- Establish a diverse mentoring team
- Seek out senior investigators in your department etc as mentors who will give you constructive criticism and advice
- Participate in ESI training/mentoring programs
- Respond to NIH guide requests for information (RFI)
- Seek out POs prior to national meetings and arrange to meet with them
- The Specific Aims section is probably the most important of the application.
 - Constitute the template or master plan for the rest of your Research Plan
 - Should include everything about your application that is important and exciting
 - Will be used by the SRO to recruit reviewers for your application
 - Most members of the study section will only read the Specific Aims (and Project Summary/Abstract) before they score your application

Resources for Researchers

Search For Resources
Search Resources for Researchers

Browse Resources
Browse resources by tool type or research area or view all (255) resources.

| Tool Type | Research Area |
|-------------------------------|--------------------------------|
| Analysis Tools (126) | Cancer Biology (101) |
| Datasets & Databases (89) | Cancer Omics (91) |
| Lab Tools (42) | Cancer Treatment (82) |
| Community Research Tools (21) | Screening & Detection (32) |
| Terminology (16) | Cancer Health Disparities (31) |
| Networks/Consortiums (12) | Causes of Cancer (27) |
| Clinical Research Tools (10) | Cancer & Public Health (23) |
| Training Resources (3) | Cancer Diagnosis (22) |
| | Cancer Prevention (20) |
| | Cancer Statistics (20) |
| | Bioinformatics (17) |
| | Cancer Survivorship (13) |

Summary



- Know the grant process
- Know your Program Director, work throughout the grant cycle
- Go to NIH or NCI seminars for investigators
- Ask peers with successful grants to read your grants
- Pay close attention to specific aims sections
- Grants must be clear and written in an easily readable & understandable fashion

DCP Resources for Researchers



NATIONAL CANCER INSTITUTE
Division of Cancer Prevention

Making cancer prevention possible

HOME

MAJOR PROGRAMS

RESEARCH GROUPS

CLINICAL TRIALS

FUNDING & GRANTS

RESOURCES

NEWS & EVENTS

ABOUT DCP

Home

Contact Us

U.S. Mail Address

Division of Cancer Prevention
National Cancer Institute
9609 Medical Center Drive
Bethesda, MD 20892

Commercial Delivery Address

Division of Cancer Prevention
National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850

For technical or navigational difficulties, contact your internet provider and/or technical support staff.

If you are still experiencing difficulty with our Web site, send a message to our [Webmaster](#).

<https://prevention.cancer.gov>

About DCP

The Division of Cancer Prevention (DCP) is the division of the National Cancer Institute (NCI) devoted to cancer prevention research. DCP provides funding and administrative support to clinical and laboratory researchers, community and multidisciplinary teams, and collaborative scientific networks.

The [National Cancer Institute](#), part of the National Institutes of Health (NIH), is the federal government's principal agency for cancer research and training. NCI's mission is to lead, conduct, and support cancer research across the nation to advance scientific knowledge and help all people to live longer, healthier lives. NCI's scope of work spans a broad spectrum of cancer research across a variety of disciplines and supports research training opportunities at career stages across the academic continuum.

Scientific Scope

The National Cancer Institute Division of Cancer Prevention (DCP) is devoted to research on cancer prevention, interception, screening and early detection, and symptom science. To accomplish this, DCP provides funding and administrative support to clinical, population science, and laboratory researchers, community and multidisciplinary teams, and collaborative scientific networks.



Commemoration of the 50th Anniversary of the National Cancer Act

The Division of Cancer Prevention honors the champions and changemakers of cancer prevention, early detection and symptom science.



Funding and Grants

Funding Opportunities

- Funded Grants
- Grantsmanship Resources
- Workforce Initiatives

Keyword Search

Program Official

- Altaf Mohammed, Ph.D.
- Asad Umar, D.V.M., Ph.D.
- Brandy Heckman-Stoddard, Ph.D., M.P.H.
- Brennan Streck, Ph.D., R.N., M.P.H.
- Claire Zhu, Ph.D.
- Edward Sauter, M.D., Ph.D.

Type of Funding Opportunity

- Any -
- Notice of Special Interest**
- PA
- PAR
- PAS
- RFA

Activity Code

- Any -

Clinical Trials Status

- Any -
- Clinical Trial Required**
- Clinical Trial Optional**
- Clinical Trial Not Allowed**
- Basic Experimental Studies with Humans (BESH) Required**

Items per page

10

Apply

Reset

Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.



Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: <https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding>.

Notice of Funding Opportunities

| Title | Announcement Number | Activity Code | Clinical Trials Status | Expiration Date | Program Official |
|--|---|---------------|----------------------------|-----------------|--|
| HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials | RFA-NS-24-023 (UG3/UH3 - Clinical Trial Optional) | UH3, UG3 | Clinical Trial Optional | 01/31/2024 | Rachel Altschuler, Ph.D. |
| NCI Cancer Moonshot Scholars Diversity Program (CMSDP) | RFA-CA-22-050 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 02/07/2024 | Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain | NOT-NS-22-087 | | | 02/16/2024 | |
| HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain | RFA-NS-22-070 (R01 Clinical Trial Not Allowed) | R01 | Clinical Trial Not Allowed | 03/07/2024 | |
| Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) | NOT-NS-20-107 | | Clinical Trial Not Allowed | 05/16/2024 | |
| Pancreatic Cancer Detection Consortium: Research Units | PAR-21-334 (U01 Clinical Trial Optional) | U01 | Clinical Trial Optional | 06/12/2024 | |
| Notice of Intent to Publish a Funding Opportunity for The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research | NOT-CA-23-081 (K12 Clinical Trial Optional) | K12 | Clinical Trial Optional | 06/17/2024 | |
| Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | NOT-NS-23-002 | | | 06/21/2024 | |
| Understanding Chronic Conditions Understudied Among Women | RFA-OD-23-013 (R21 Clinical Trial Optional) | R21 | Clinical Trial Optional | 06/21/2024 | Goli Samimi, Ph.D., M.P.H. |
| Understanding Chronic Conditions Understudied Among Women | RFA-OD-23-014 (R01 Clinical Trial Optional) | R01 | Clinical Trial Optional | 06/21/2024 | Goli Samimi, Ph.D., M.P.H. |

DCP's Current Funding Opportunities (R01)

| Title | NCI# | Clinical Trial | Expiration Date | Contacts |
|--|-------------------------------|----------------|-----------------|--|
| NCI Cancer Moonshot Scholars Diversity Program (CMSDP) | RFA-CA-22-050 | Optional | 02/07/2024 | Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer | NOT-CA-23-018 | | 09/08/2024 | Gary Della Zanna, DO |
| Understanding Chronic Conditions Understudied Among Women | RFA-OD-23-014 | Optional | 06/21/2024 | Goli Samimi, Ph.D., M.P.H. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery | PAR-21-331 | Optional | 09/08/2024 | Edward Sauter, M.D., Ph.D. |
| Basic Research in Cancer Health Disparities | PAR-21-322 | Not Allowed | 09/08/2024 | Asad Umar, D.V.M., Ph.D. |
| Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity | PAR-22-092 | #N/A | 09/08/2024 | Ellen Richmond, M.S., G.N.P.-B.C. |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research | RFA-CA-24-012 | Optional | 10/02/2024 | Guillermo Marquez, Ph.D. |
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies | PAR-21-329 | Optional | 11/06/2024 | Rachel Altshuler, Ph.D. |
| HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment | RFA-NS-22-034 | Not Allowed | 12/07/2024 | Rachel Altshuler, Ph.D. |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer | PAR-22-061 | Not Allowed | 01/08/2025 | Young Kim, Ph.D. |
| Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities | PAR-22-064 | Optional | 01/08/2025 | Ellen Richmond, M.S., G.N.P.-B.C. |
| HEAL Initiative: Understanding Individual Differences in Human Pain Conditions | RFA-NS-24-021 | Optional | 02/07/2025 | Rachel Altshuler, Ph.D. |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-22-099 | Optional | 05/08/2025 | Richard Mazurchuk, Ph.D. |
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes | PAR-22-131 | Optional | 09/08/2025 | Richard Mazurchuk, Ph.D. |
| Biology of Bladder Cancer | PAR-22-218 | Optional | 09/08/2025 | |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics | PAR-23-279 | Optional | 01/08/2027 | Edward Sauter, M.D., Ph.D. |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis | PAR-24-085 | Required | 01/08/2027 | Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Cancer Prevention and Control Clinical Trials Grant Program | PAR-24-072 | Required | 01/08/2027 | Brandy Heckman-Stoddard, Ph.D., M.P.H. |



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol

Division of Cancer Treatment and Diagnosis- Funding Opportunities and Research Resources

Sundar Venkatachalam, Branch Chief, Preclinical Therapeutics Grants Branch,
DTP, DCTD, NCI, National Institutes of Health

Overview

- **Division of Cancer Treatment and Diagnosis (DCTD)**
- **Grant Funding Opportunities and Resources**
- **Navigating the Grant Application Process**
- **Applicant Resources**

Division of Cancer Treatment and Diagnosis (DCTD)

Biometric Research Program

Cancer Diagnosis Program

Cancer Imaging Program

Cancer Therapy Evaluation Program

Developmental Therapeutics Program

Radiation Research Program

Translational Research Program

Office of Cancer Clinical Proteomics Research

Office of Cancer Complementary and Alternative Medicine

Developmental Therapeutics Program (DTP)

Discovery to IND-enabling support through:

1. Grants
2. Repositories
3. Access to Development Resources & Services
4. Expertise

DTP Funding, Resources and Services

Preclinical Therapeutics Grants Branch

Grants: Small Molecule, Natural Product, drug targets, discovery & development of novel therapeutic concepts

Immuno-oncology Branch

Grants: Immuno-oncology
Canine Immunotherapy Network
Pediatric Immunotherapy Network
Cancer Adoptive Cell Therapy (CanACT)

Biological Resources Branch

Grants: Biopharmaceutical discovery & development
Services: Development of clinical grade biologics, adoptive cell therapies, analytical testing (at FNLCR)
Repository: Biologics (MAbs, cytokines)

Information Technology Branch

Resources: Extensive databases of compounds, activity/efficacy, computational tools (COMPARE, ALMANAC)

Natural Products Branch

Repository: Large pre-fractionated library; collections of extracts (marine, plant, soil, fungi)
Services: Natural product chemistry

Molecular Pharmacology Branch

Services: NCI-60 tumor cell screen
Patient-derived models screen, target validation, combinatorial screening

Drug Synthesis & Chemistry Branch

Repository: NCI Compound Repository
Services: Synthetic chemistry, route optimization, scale-up

Biological Testing Branch

Resources: Tumor repository, Patient Derived Tumor Models repository
Services: Model development, efficacy, dose schedule, MTD

Toxicology & Pharmacology Branch

Services: Non-GLP and GLP PK & toxicology, ADME, *in vitro* tox screening
Investigative Toxicology Laboratory: *in vitro* assays

Pharmaceutical Resources Branch

Services: Large scale GMP manufacture
bulk API, analytical testing, dose formulation development, stability studies for final drug product

Preclinical Therapeutics Grants Branch (PTGB)


PTGB supports pre-clinical research focused on discovery, development and evaluation of anti-cancer agents with an emphasis on small molecules.

Preclinical Therapeutics Grants Branch


Grant portfolio for small molecule therapeutics discovery & development:

- Molecular targets in cancer
- Biochemistry
- Synthetic/Medicinal Chemistry
- Mechanism of action
- Efficacy in model systems
- Pharmacology & Toxicology
- Mechanisms of resistance
- Novel delivery & Nanotherapeutics


Active Awards - Top Targets



Active Awards by Organ/System



Primary Topic Areas (R01s)



Notices of Funding Opportunities (NOFOs)

Types of Grant Opportunities

Parent Announcements

- Non-specific, investigator-initiated “unsolicited” research
- May submit any topic within the breadth of the NIH mission
- No money set-aside
- Reviewed by standing study sections
- Competition tied mainly to an institutes' overall pay line

Institute Specific Program Announcements (PA)

- Often broadly defined or a reminder of a scientific need
- Competition tied mainly to the institute’s overall pay line

2 Subtypes:

- PAR – special review
- PAS – institute commits a budget

Notice of Special Interest (NOSIs)

Requests for Applications (RFA)

- NIH-Requested Research; Well-defined scientific area
- Set-aside funds and targets number of awards
- Special review panels
- Competition depends on number of applicants and dollars set aside

Funding Mechanisms- Examples

| | R01 | R21 | R03 | R15 |
|-----------------------------------|--|------------------------------|---------------------------------|--|
| Project Period | Up to 5 years | 2 years | 2 years | 3 years |
| Direct Costs limit | ≤ \$250K (modular) < \$250K but <\$500K (non-mod) | \$275K | \$100K | \$300K |
| NCI Payline (FY24;interim) | 9% (EI/NI) 14% (ESI) | 9% | Scores up to and including 25 | Scores up to and including 25 |
| Key Features | Preliminary data in place; large award | Exploratory; data collection | Small projects; data collection | Only for R15 eligible institutions; training focus |

Current DTP - PTGB Funding Opportunities

| FOA # | Title |
|----------------------|---|
| PAR-23-264 | Assay development and screening for discovery of chemical probes or therapeutic agents (R01) |
| NOT-CA-21-101 | Advancing the development of tumor site-activated small molecules (R21 and R01) |
| PAR-22-216 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
| PA-20-185 | NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) |

NIH Grants Process Overview

Researcher



Scientific Review Officer (SRO)



Scientific Review Panel (CSR/IC)




Scientists evaluate scientific merit of grant proposal



Program Officer (PO)



Main contact for applicant
Helps interpret review results



Institute National Advisory Councils



Assess programs
Approve applications
Public members



Funding based on pay line

Initiates grant proposal:

- New project
- Revision
- Continuing project

Additional Information

Program Directors (IC Specific)

- **Before Submission:**
 - Guidance on proposal
 - Funding Opportunities
- **After review:**
 - Summary Statement

Scientific Review Officers (CSR and IC specific)

- **Before Submission:**
 - Guidance on Study Sections
 - Policy guidance on application
 - Policy guidance on review

Investigator Initiated Applications

Expectations (R01):

- **Strong Preliminary Data**
- **Compelling Hypothesis**
- **Innovative Science**
- **PI's Track Record/Expertise**

New Applicants

Useful tips:

- **Attend grant writing workshops/seminars**
- **Start early with grant preparation**
- **Contact program director (early)**
- **Get input from senior colleagues**
- **Submit ONE (only one) application/cycle**
- **Put your best science forward**
- **Get your important manuscript(s) published**

Online Resources for Applicants

DCTD funding opportunities:

<https://dctd.cancer.gov/FundingPartnerships/PAsRFAs.htm>

CSR links for Applicants:

<https://public.csr.nih.gov/ForApplicants>

Study section information (Translational/Oncology):

<https://public.csr.nih.gov/StudySections/DTCS/CTH>

To become an Early Career Reviewer:

<https://public.csr.nih.gov/ForReviewers/BecomeAReviewer/ECR/BecomeanEarlyCareerReviewer>

PTGB Members

- Joseph Agyin, Ph.D.
 - Weiwei Chen, Ph.D.
 - David Covell, Ph.D.
 - Suzanne L. Forry, Ph.D.
 - Yali Fu, Ph.D.
 - Will Greenberg, Ph.D.
 - Sudhir B. Kondapaka, Ph.D.
 - Morgan O'Hayre, Ph.D.
 - Sundar Venkatachalam, Ph.D.
- <https://ntp.cancer.gov/organization/ptgb/default.htm>



Introduction to NIH/NCI Grants System from a Program Director's Perspective

Center to Reduce Cancer Health Disparities

CENTER TO REDUCE
CANCER HEALTH DISPARITIES

NCI Transition Career Development Workshop

Tiffany Wallace, PhD



Agenda

1. *CRCHD Mission and Priorities*
2. *Funding Opportunities*
 - *Disparities Research*
 - *Workforce Diversity*
3. *How to find funding opportunities*

NCI Center to Reduce Cancer Health Disparities (CRCHD)

CRCHD Mission

- **Advance cancer disparities research** across the entire cancer continuum.
- **Advise** on strategic planning and policies related to cancer disparities research and diversity training.
- Lead NCI's efforts in **increasing workforce diversity**.

The National Cancer Plan



Goal 4: Eliminate Inequities

Disparities in cancer risk factors, incidence, treatment side effects, and mortality are eliminated through equitable access to prevention, screening, treatment, and survivorship care

Goal 6: Engage Every Person

Every person with cancer or at risk for cancer has an opportunity to participate in research or otherwise contribute to the collective knowledge base, and barriers to their participation are eliminated.

Goal 8: Optimize the Workforce



The cancer care and research workforce is diverse, reflects the communities served, and meets the needs of all people with cancer and those at risk for cancer, ensuring they live longer and healthier lives

CRCHD Focus Areas

Diversity Training



Workforce Diversity




Partnerships

Partnership to Advance Cancer Health Equity (PACHE)



Networks



Disparities and Equity Program

Basic and translational research



A large blue diagonal graphic on the left side of the slide, consisting of a solid blue triangle and a lighter blue border.

Agenda


1. *CRCHD Mission and Priorities*
2. *Funding Opportunities*
 - *Disparities Research*
 - *Workforce Diversity*
3. *How to find funding opportunities*

Contributors to Cancer Disparities

- The causes of health disparities are multifactorial, inter-related and complex
- *All directly influenced by structural and systemic racism.*

FIGURE 5

Why Do U.S. Cancer Health Disparities Exist?




Research Initiatives for Disparities Research Span Numerous Disciplines

Basic Research

- Basic Research in Cancer Health Disparities (*R03, R21, R01*)
- Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (*R21, R01*)

Social Science

- Admin Supplements Investigating how SDOH and Cancer Care Inequalities Contribute to Disparities in HIV-associated Cancers



Translational/Clinical Research

- NCI Clinical and Translational Exploratory/ Developmental Studies (*R21*)
- Specialized Programs of Research Excellence (SPOREs) (*P20, P50*)
- PDX Development and Trial Centers Research Network (PDXNet) (*U54, U24*)


Transdisciplinary and Multidisciplinary Research

- Admin Supplements to Support Cancer Disparity Collaborative Research


Basic Research in Cancer Health Disparities Program

- **PAR-21-322 (R01), PAR-21-323 (R21), PAR-21-324 (R03)**
- **Supports research within Division of Cancer Biology (DCB) and Division of Cancer Prevention (DCP)**
- **Purpose: Support innovative basic research investigating the biological and genetic contributions of cancer disparities.**
- **Projects may seek to:**
 - Investigate mechanistic studies of biological factors associated with cancer disparities
 - Develop and test new methodologies and models
 - Conduct secondary data analyses
- **Last submission dates in June and July, 2024**

Cancer Categories (n=53) for Active Awards in FY2022



Populations Studied (n=53) Across Active FY22 Awards



Contact

Tiffany Wallace, Ph.D.
Tiffany.Wallace@nih.gov

NCI Clinical and Translational Exploratory/ Developmental Studies

- **PAR-22-216 (R21)**
- **Supports research within the Division of Cancer Treatment and Diagnosis (DCTD), Division of Prevention (DCP), and CRCHD**
- **Purpose:** Support preclinical and early phase clinical research directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities
- **Projects may propose:**
 - Clinical studies
 - Correlative Studies/Biomarker Development
 - Target and Agent Development
 - Model Development and Analysis
- **Last submission date: July 01, 2025**

Contact for disparity research


Tiffany Wallace, Ph.D.

Tiffany.Wallace@nih.gov


Admin Supplements to Support Cancer Disparity Collaborative Research

- **PAR-22-114**
- **Purpose:** To catalyze and broaden research and collaborations across the cancer disparity research spectrum
- **Primary Objectives**
 - Promote new cancer disparities research and collaborations
 - Envisioned to accelerate and strengthen multidisciplinary cancer disparities research
 - Increase the number and competitiveness of cancer disparity-related grant proposals submitted to the NCI
- **Last submission date:** January 23, 2025

Research Areas of Awarded Applications



Parent Grant Activity Codes



Contacts

Dr. Jay Revilleza
mrevilleza@nih.gov

Dr. Sarah Szurek
sarah.szurek@nih.gov

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research

- **PAR-24-039 (R21)**
- **Purpose:** Enhance diversity of the cancer research workforce by supporting eligible [New Investigators](#) and [Early State Investigators](#) from backgrounds known to be underrepresented in biomedical research.
- **Goal:** Advance **basic research on the biology of cancer** while supporting eligible researchers to develop preliminary data for competitive R01 proposals.
- **Eligibility/Limit:** An individual cannot have a previous R01 (or equivalent) and may receive no more than 2 awards from the current, past or future iteration of this NOFO.
- **Last submission date is November 18, 2026**




Contacts

Sangeeta Ghosh, PhD
sangeeta.ghosh@nih.gov

Laritzia M. Rodriguez, MD., PhD.
laritzia.rodriquez@nih.gov

Cancer Moonshot Scholars program

- **RFA-CA-22-050 (R01)**
- **Purpose:** Advance cancer research, while also diversifying the pool of researchers and the approaches to cancer research that NCI funds.
- **Aligned with the goals for new phase of the Cancer Moonshotsm**
 - Inspire and support the next generation of diverse, innovative cancer researchers
 - Increase diversity of cancer research and care workforce to better resemble the communities we serve
- **Last submission date is February 06, 2024**



Eligibility and Research Scope for RFA-CA-22-050

1. Proposed research must align with the NCI's scientific mission
2. Contact PIs must be an Early-Stage Investigator
 - MPI applications are allowed, however only the contact PI must be an ESI
3. Contact PIs must include an Institutional Eligibility Letter describing their contribution to the RFA goals

NCI Mission and Scope



<https://www.cancer.gov/about-nci/overview>



NCI's Early Investigator Advancement Program (EIAP), aims to promote the transition of exceptional junior cancer researchers and clinician scientists from diverse backgrounds to become established investigators.



Geared for New (NI) or Early-Stage Investigators (ESI) seeking an R01 or R01-equivalent grant

Program Components

- R01 Grant Writing Workshop
- Grantsmanship consultations
- Mentored Mock Review (MMR) session
- Engagement with a volunteer mentor
- Career development workshops webinars, and support
- Peer Networking

Application Timeline



Application Requirements: <https://www.cancer.gov/about-nci/organization/crchd/diversity-training/eiap>

A large blue diagonal graphic on the left side of the slide, consisting of a dark blue triangle and a lighter blue triangle meeting at a diagonal line.

Agenda

1. *CRCHD Mission and Priorities*
2. *Funding Opportunities*
 - *Disparities Research*
 - *Workforce Diversity*
3. *How to find funding opportunities*

So many options...



Resources to help get you started:

- NIH Guide for Grants and Contracts (NIH wide)
- Grants.gov (federal wide)
- NCI Divisions, Offices, and Centers websites
- Speak with a Program Officer
- NIH RePORTER / MatchMaker
- Advisory Meetings

NIH-wide and federal-wide searches

<https://grants.nih.gov/funding/index.htm>

NIH GRANTS & FUNDING
NIH Central Resource for Grants and Funding Information

Search this Site

eRA | NIH Sta

HOME ABOUT GRANTS **FUNDING** POLICY & COMPLIANCE NEWS & EVENTS

Home » Funding

FUNDING

Find Grant Funding: NIH Guide to Grants and Contracts

Other Transactions

Contracts

Research Training and Career Development

Extramural Diversity

NIH Funding Strategies

Funding

NIH offers funding for many types of grants, contracts, and even programs that help repay loans for researchers. Learn about these programs, as well as about NIH's budget process, grant funding strategies, and policies, and more.

Find Grant Funding

(NIH Guide to Grants and Contracts)

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide

<https://www.grants.gov/>

HELP REGISTER LOGIN

SEARCH Grant Opportunities Enter Keyword... GO

HOME LEARN GRANTS SEARCH GRANTS APPLICANTS GRANTORS SYSTEM-TO-SYSTEM FORMS CONNECT SUPPORT

Some users are experiencing intermittent difficulty accessing Grants.gov. HHS is working to resolve the issue as quickly as possible.

Convenience Comes to Federal Grants

Download the Grants.gov Mobile App to search and submit on the go.

Download on the App Store GET IT ON Google Play

Reminder: Federal agencies do not publish personal financial assistance opportunities on Grants.gov. Federal funding opportunities published on Grants.gov are for organizations and entities supporting the development and management of government-funded programs and projects. For more information about personal financial assistance benefits, please visit Benefits.gov.

SEARCH GRANTS GET STARTED GRANT POLICIES GRANT-MAKING AGENCIES PREVENT SCAMS COMMUNITY BLOG TWITTER FEED YOUTUBE VIDEOS USER GUIDE SUPPORT CENTER

NCI Extramural Divisions and Centers

Extramural

DIVISION OF CANCER BIOLOGY

DCB encourages and facilitates continued support of basic research in all areas of cancer biology to provide the research foundation which enables improved understanding of the disease and may lead to new approaches for prevention, diagnosis, and treatment.

DIVISION OF CANCER PREVENTION

DCP conducts and supports research to find ways to prevent and detect cancer, and to prevent or relieve symptoms from cancer and its treatments.

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES

DCCPS conducts and supports an integrated program of genetic, epidemiological, behavioral, social, applied, and surveillance cancer research to reduce risk, incidence, and deaths from cancer as well as enhance the quality of life for cancer survivors.

DIVISION OF CANCER TREATMENT AND DIAGNOSIS

DCTD supports the translation of promising research into clinical applications to improve the diagnosis and treatment of cancer in areas of unmet need that are often too risky or difficult for industry or academia to develop alone.

Office of the Director

- Center for Biomedical Informatics and Information Technology Center for Cancer Genomics
- Center for Cancer Training
- Center for Global Health
- Center to Reduce Cancer Health Disparities
- Center for Research Strategies
- Center for Strategic Scientific Initiatives
- Coordinating Center for Clinical Trials

Meet NIH Program Directors that match with your research

- Talk with NIH Program Directors
- Over 245 Program Directors at NCI, all having distinct expertise and portfolios
- NIH RePORTER, Matchmaker
<https://reporter.nih.gov/>


The screenshot shows the NIH RePORTER website. At the top, there is a navigation bar with the NIH logo, 'RePORT' and 'RePORTER' text, and links for 'FAQs', 'API', 'EXPORTER', and 'Sign In'. Below the navigation bar is a 'Quick Search' section with a search input field and a 'Search' button. A 'Welcome to the NIH RePORTER' message is displayed on the right, mentioning that each award supported by NIH promotes efforts to seek fundamental knowledge about the nature and behavior of living systems and/or the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Below the search and welcome messages are two charts: 'Active Funding by State' (a map of the United States) and 'Active Projects by Institute/Center' (a bar chart showing the number of active projects for various NIH institutes/centers). At the bottom, there is an 'Advanced Projects Search' section with input fields for 'Fiscal Year', 'Principal Investigator (PI)', and 'Organization'. A 'Matchmaker' section is highlighted with a red circle, containing the text 'Find potential Program Officials, ICs, and review panels for your research.' and a 'Get Started' button.

NCI Advisory Board Meetings help to keep you informed on what's coming

<https://deainfo.nci.nih.gov/advisory/index.htm>

- Agendas, slides, and videocast available for all NCI advisory meetings:
 - Board of Scientific Advisors (BSA)
 - National Cancer Advisory Board (NCAB)
 - Clinical Trials and Translational Research Advisory Comm. (CTAC)
 - NCI Council Of Research Advocates (NCRA)
 - Frederick National Laboratory Advisory Committee (FNLAC)
- **Board of Scientific Advisors (BSA)**
 - **Function Statement:** Provide scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the NCI's extramural research programs, and **concept review of extramural program initiatives.**

8th Virtual Joint Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board



NCI Director's Report


Douglas R. Lowy, M.D.
Acting Director, National Cancer Institute

8th Virtual Joint Meeting of the Board of Scientific Advisors and the National Cancer Advisory Board

November 30, 2023
07:04 / 3:29:55

@NCIDirector
The NCI

8th Virtual Joint Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board



FY24 Interim Paylines Announced

| FY24 Interim Paylines for NCI Competing Grants Effective November 2, 2023 | |
|--|-----------------------------|
| Grant Type | Interim Payline |
| R01 Grants for Established & New Investigators | 9 th Percentile |
| R01 Grants for Early-Stage Investigators | 14 th Percentile |
| R21 Exploratory Grants | 9 th Percentile |

NCI will generally fund noncompeting grants at 90% of the committed level.

34:23 / 3:29:55

Learn more: NCI Bottom Blog
www.cancer.gov/grants-training/nci-bottom-line-blog

Stay Connected

Have questions?

Tiffany.Wallace@nih.gov

More information



@ncicrhd



NCI Center to Reduce Cancer
Health Disparities (CRCHD)



<http://crchd.cancer.gov>



**NATIONAL
CANCER
INSTITUTE**

cancer.gov/crchd